Medical progress cannot afford to move slower than the disease itself. The PSOGI 2025 Manifesto is a wake-up call: research into peritoneal cancer has historically been insufficient. At Viamed, through IVOQA, we work to reverse this situation by integrating constant innovation into our daily practice to offer solutions where there were once only limitations.
A Future Where Science Advances at the Speed of Hope
Currently, many standard treatments for peritoneal malignancies are perceived as limited or overly invasive. The challenge is not only to cure but to do so in the most precise and least aggressive way possible, based on real-world data and state-of-the-art technology.
Current Challenges: Why is Research Moving Slowly?
The manifesto identifies the obstacles that the Viamed Institute of Advanced Surgical Oncology helps to combat:
- Low Investment: As these are uncommon diseases, public and private investment is often lower than in other types of cancer.
- Scientific Fragmentation: Researchers’ efforts are often not coordinated at an international level.
- Lack of Long-term Data: There is a shortage of biobanks and centralized registries that allow for the study of recurrence and quality of life years after treatment.
- Barriers to Innovation: Administrative delays mean that promising techniques take years to reach the operating room.
The IVOQA Response: Innovation Without Barriers
At IVOQA, under the leadership of Dr. Delia Cortés Guiral, we are not mere spectators of science; we are active participants in its evolution:
- Leadership in Minimally Invasive Techniques: We are pioneers in implementing and perfecting techniques such as ePIPAC (Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy), which offers a less invasive alternative for selected patients.
- International Collaboration Networks: We collaborate with expert networks to share data and outcomes, ensuring that our patients’ experiences contribute to the global knowledge base.
- Outcome-Based Medicine: We focus not only on surgery but also on long-term follow-up, analyzing quality-of-life data so that innovation has a real and positive impact on the patient’s daily life.
Research is the only path to turning peritoneal cancer into a controllable and curable disease in all cases. At IVOQA and Viamed, our commitment is that every patient benefits today from the medicine of tomorrow.
Do you want to know the most innovative treatment options for your case? Consult with Dr. Delia Cortés at IVOQA and discover how advanced technology can change your prognosis.
